CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Talimogene Laherparepvecbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03663712
NCT03663712Phase 1Completed
CompareCT.gov

A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

Dan Blazer III, M.D.·interventional·Posted Sep 10, 2018·Updated Nov 20, 2024

In Brief

A Phase 1 clinical trial evaluating Talimogene Laherparepvec for Peritoneal Surface Malignancy. Completed, enrolled 28 participants across 3 sites.

Detailed Summary

The primary objective of this open-label, Phase I, trial is to evaluate the toxicity profile of intraperitoneal talimogene laherparepvec (TVEC) in patients with peritoneal surface dissemination from gastrointestinal or recurrent, platinum-resistant ovarian tumors. The secondary objectives are to evaluate the pharmacokinetic profile and viral shedding of TVEC by measuring viral load in serum and urine as well as viral load in peritoneal washings.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeritoneal Surface Malignancy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 10, 2018
Enrollment StartMay 23, 2019
Primary CompletionOct 13, 2022
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.8 years ago

Interventions

Talimogene Laherparepvecbiological

TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells